EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus

Gerald C So iD, Jessica Bo Li Lu, Sachiko Koyama, Ying-Hua Cheng, Debora L Gisch iD, Kelsey McClara, Paul R Dexter, Asif A Sharfuddin, Jumar Etkins, Emma M Tillman iD, Travis R Beamon, Zachary Cowsert und 3 weitere

Clinical Pharmacology & Therapeutics · 2025-03 · 117 (3) · 716-723

DOI: 10.1002/cpt.3504 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 27.11.2024. Verfasst von Gerald C So und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Cannabidiol, Tacrolimus, Cytochrome P-450 CYP3A Inhibitors, Immunosuppressive Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCCIH NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One in six Americans uses cannabidiol‐based or cannabis‐derived products. Cannabidiol is a substrate of CYP3A, but its role as a potential CYP3A inhibitor remains unclear. We hypothesized that cannabidiol would inhibit CYP3A‐mediated metabolism of tacrolimus. This report is an interim analysis of an open‐label, three‐period, fixed‐sequence, crossover study in healthy participants. Participants first received a single dose of tacrolimus 5 mg orally. After washout, participants later received cannabidiol titrated to 5 mg/kg twice daily for 14 days to reach a steady state, followed by a second single dose of tacrolimus 5 mg orally. Tacrolimus concentrations in whole blood were measured by UHPLC–MS/MS method. Pharmacokinetic parameters were calculated by noncompartmental analysis. Twelve participants completed all periods of the study. The maximum concentration ( C max ) of tacrolimus increased 4.2‐fold ( P < 0.0001) with cannabidiol (40.2 ± 13.5 ng/mL) compared with without cannabidiol (9.85 ± 4.63 ng/mL). The area under the concentration‐vs.‐time curve (AUC 0‐∞ ) increased 3.1‐fold ( P < 0.0001). No change in half‐life ( t 1/2 ) was observed. This study demonstrates that cannabidiol increases tacrolimus exposure. Our data suggest the need for dose reduction in tacrolimus and frequent therapeutic dose monitoring in transplant patients taking cannabidiol concomitantly. Whether this observed interaction occurred due to the inhibition of CYP3A4 and/or CYP3A5 in the liver, intestine, or both, or intestinal drug transporters (e.g., p‐glycoprotein) during the first‐pass elimination remains to be elucidated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolTacrolimusCytochrome P-450 CYP3A InhibitorsImmunosuppressive AgentsHumansMaleCross-Over StudiesDrug InteractionsAdultFemaleCytochrome P-450 CYP3AYoung AdultMiddle AgedArea Under CurveHealthy VolunteersAdministration, OralTandem Mass Spectrometry

Substanzen

CannabidiolTacrolimusCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Gerald C So, Debora L Gisch, Emma M Tillman, Zeruesenay Desta, Michael T Eadon

Förderung

  • NCCIH NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

So, G. C., Lu, J. B. L., Koyama, S., Cheng, Y. H., Gisch, D. L., McClara, K., Dexter, P. R., Sharfuddin, A. A., Etkins, J., Tillman, E. M., Beamon, T. R., Cowsert, Z., Stuart, J. S., Desta, Z., & Eadon, M. T. (2025). A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus. Clinical Pharmacology & Therapeutics, 117(3), 716-723. https://doi.org/10.1002/cpt.3504

Vancouver

So GC, Lu JBL, Koyama S, Cheng YH, Gisch DL, McClara K, et al. A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus. Clinical Pharmacology & Therapeutics. 2025;117(3):716-723. doi:10.1002/cpt.3504

BibTeX
@article{So2025,
  author = {So, Gerald C and Lu, Jessica Bo Li and Koyama, Sachiko and Cheng, Ying-Hua and Gisch, Debora L and McClara, Kelsey and Dexter, Paul R and Sharfuddin, Asif A and Etkins, Jumar and Tillman, Emma M and Beamon, Travis R and Cowsert, Zachary and Stuart, Jennifer S and Desta, Zeruesenay and Eadon, Michael T},
  title = {A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {3},
  pages = {716--723},
  doi = {10.1002/cpt.3504}
}
Kostenlos starten →